REMINGTON JACK 4

4 · Ardea Biosciences, Inc./DE · Filed May 21, 2009

Form 4

Period: 2009-05-20

Director

Transactions

Exercise/Conversion
Common Stock
2009-05-20$5.85/sh+2,500$14,625→ 26,000 total
Exercise/Conversion
Common Stock
2009-05-20$5.85/sh+1,250$7,313→ 28,500 total
Exercise/Conversion
Stock Option (Right to Buy)
2009-05-20−10,000→ 0 total
Exercise: $4.08Exp: 2015-01-02→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2009-05-20−12,500→ 0 total
Exercise: $4.36Exp: 2017-01-02→ Common Stock (12,500 underlying)
Exercise/Conversion
Common Stock
2009-05-20$4.08/sh+10,000$40,800→ 11,000 total
Exercise/Conversion
Common Stock
2009-05-20$5.85/sh+1,250$7,313→ 27,250 total
Exercise/Conversion
Stock Option (Right to Buy)
2009-05-20−2,500→ 0 total
Exercise: $5.85Exp: 2017-06-14→ Common Stock (2,500 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2009-05-20−1,250→ 0 total
Exercise: $5.85Exp: 2017-06-14→ Common Stock (1,250 underlying)
Exercise/Conversion
Common Stock
2009-05-20$4.36/sh+12,500$54,500→ 23,500 total
Sale
Common Stock
2009-05-20$14.95/sh−27,500$411,045→ 1,000 total
Exercise/Conversion
Stock Option (Right to Buy)
2009-05-20−1,250→ 0 total
Exercise: $5.85Exp: 2017-06-14→ Common Stock (1,250 underlying)

Footnotes (2)

[F1]Immediately exercisable, subject to a right of repurchase on behalf of the Issuer that lapsed one year from the grant date.
[F2]Immediately exercisable, subject to a right of repurchase on behalf of the Issuer that lapsed on January 2, 2008.

Documents

1 file